Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics 45: Novel Targets for Therapy

Heparin binding epidermal growth factor like growth factor (HB) is a promising target for human cancer therapy.

Fusanori Yotsumoto, Shingo Miyamoto, Hiroshi Yagi, Hiroshi Tsujioka, Toru Hachisuga, Tatsuhiko Kawarabayashi and Eisuke Mekada
Fusanori Yotsumoto
Fukuoka University, Fukuoka, Japan, Kyushu University, Fukuoka, Japan, Osaka University, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shingo Miyamoto
Fukuoka University, Fukuoka, Japan, Kyushu University, Fukuoka, Japan, Osaka University, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Yagi
Fukuoka University, Fukuoka, Japan, Kyushu University, Fukuoka, Japan, Osaka University, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Tsujioka
Fukuoka University, Fukuoka, Japan, Kyushu University, Fukuoka, Japan, Osaka University, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toru Hachisuga
Fukuoka University, Fukuoka, Japan, Kyushu University, Fukuoka, Japan, Osaka University, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatsuhiko Kawarabayashi
Fukuoka University, Fukuoka, Japan, Kyushu University, Fukuoka, Japan, Osaka University, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eisuke Mekada
Fukuoka University, Fukuoka, Japan, Kyushu University, Fukuoka, Japan, Osaka University, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2006
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 47, 2006

Abstract

5511

[Introduction]We have demonstrated that HB plays a pivotal role in tumorgenicity in ovarian cancer. To explore the possibility that HB can be recognized as a target molecule for other cancers, we investigated the primacy of HB expression among EGFR ligands and antitumor effects of a specific inhibitor against HB, CRM197, on nude mice in a variety of human cancer cells.[Method]Human Ovarian cancer (5 cell lines), cervical adenocarcinoma (2 cell lines), endometrial cancer (3 cell lines), breast cancer (4 cell lines),gastric cancer (2 cell lines), lung cancer (5 cell lines), and malignant melanoma (3 cell lines) were used. Each mRNA expression level of seven EGFR ligands, including HB, EGF, amphiregulin, TGF alpha, epiregulin, betacellulin, epigen, EGFR, and GAPDH was examined by real-time quantitative PCR. To determine the mRNA expression levels of EGFR ligands and EGFR, we used the mRNA expression index (EI), which is a relative mRNA expression level standardized by GAPDH. The mRNA EI was calculated as follows: mRNA EI = (copy numbers of each EGFR ligand or EGFR mRNA/copy numbers of GAPDH mRNA) × 105 arbitrary units. To assess the antitumor effect of CRM 197, CRM 197 was injected intraperitoneally into tumor-bearing mice every week (50mg/kg/week ), when each human cancer cell (5×106cells) was subcutaneously inoculated on nude mice at 5 weeks of age and each tumor volume was over 70 mm3. Each tumor volume was estimated from two dimensional tumor measurements,tumor volume(mm3) = length ×width2/2. The values for each EGFR ligands and tumor volume were analyzed using Mann-Whitney U test. P<0.05 was considered statistically significant.[Result]Expression indices of HB showed more than 5∼10 times, compared with the expression of other EGFR ligands in all the cells except for lung cancer cells. The predominant expression of EGFR ligand in common was not found only in lung cancer cells. However, the second highest expressed molecule among EGFR ligands was not always identical in all the cancer cells. Expression of EGFR was detected in all the cancer cells. In 3 cell lines of ovarian cancers, one cell line of breast cancer, 3 cell lines of gastric cancer, and one cell line of malignant melanoma, a tumor formation was confirmed on nude mice after inoculation of cells. In the administration of CRM197, the tumor volume on treated mice was significantly reduced, compared to that on untreated mice in ovarian (3 cell lines), breast (one cell line), gastric (3 cell lines) cancer, and malignant melanoma (one cell line). However, there was no significant difference in the tumor volume between the treatment and untreatment of CRM197 in both lung cancer cells. Taken together, these results suggested that HB may be involved in tumor formation of many human cancers.[Conclusion]HB is recognized as a promising target molecule for a variety of human cancers, and CRM 197 is a possibly useful tool for cancer therapy.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 66 (8 Supplement)
April 2006
Volume 66, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Heparin binding epidermal growth factor like growth factor (HB) is a promising target for human cancer therapy.
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Heparin binding epidermal growth factor like growth factor (HB) is a promising target for human cancer therapy.
Fusanori Yotsumoto, Shingo Miyamoto, Hiroshi Yagi, Hiroshi Tsujioka, Toru Hachisuga, Tatsuhiko Kawarabayashi and Eisuke Mekada
Cancer Res April 15 2006 (66) (8 Supplement) 1296;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Heparin binding epidermal growth factor like growth factor (HB) is a promising target for human cancer therapy.
Fusanori Yotsumoto, Shingo Miyamoto, Hiroshi Yagi, Hiroshi Tsujioka, Toru Hachisuga, Tatsuhiko Kawarabayashi and Eisuke Mekada
Cancer Res April 15 2006 (66) (8 Supplement) 1296;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • siRNA for p53R2 inhibits increases in p53R2 expression following exposure to DNA damaging agents.
  • Silencing mTOR signal by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells.
  • bFGF as a therapeutic target for chemosensitization in colorectal cancer.
Show more Experimental and Molecular Therapeutics 45: Novel Targets for Therapy
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement